These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 34215324)

  • 1. Imaging biomarkers for evaluating tumor response: RECIST and beyond.
    Ko CC; Yeh LR; Kuo YT; Chen JH
    Biomark Res; 2021 Jul; 9(1):52. PubMed ID: 34215324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Objective response rate assessment in oncology: Current situation and future expectations.
    Aykan NF; Özatlı T
    World J Clin Oncol; 2020 Feb; 11(2):53-73. PubMed ID: 32133275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging response assessment for oncology: An algorithmic approach.
    Ruchalski K; Dewan R; Sai V; McIntosh LJ; Braschi-Amirfarzan M
    Eur J Radiol Open; 2022; 9():100426. PubMed ID: 35693043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphologic and Metabolic Comparison of Treatment Responsiveness with 18Fludeoxyglucose-Positron Emission Tomography/Computed Tomography According to Lung Cancer Type.
    Börksüz MF; Erselcan T; Hasbek Z; Yücel B; Turgut B
    Mol Imaging Radionucl Ther; 2016 Jun; 25(2):63-9. PubMed ID: 27277322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual-Energy Computed Tomography-Based Iodine Quantitation for Response Evaluation of Lung Cancers to Chemoradiotherapy/Radiotherapy: A Comparison With Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography-Based Positron Emission Tomography/Computed Tomography Response Evaluation Criterion in Solid Tumors.
    Ren Y; Jiao Y; Ge W; Zhang L; Hua Y; Li C; Zhai W; Tang X; He W; Fang M; Zheng X
    J Comput Assist Tomogr; 2018; 42(4):614-622. PubMed ID: 29613988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of PERCIST and RECIST criteria for evaluation of therapy response after yttrium-90 microsphere therapy in patients with hepatocellular carcinoma and those with metastatic colorectal carcinoma.
    Sager S; Akgün E; Uslu-Beşli L; Asa S; Akovali B; Sahin O; Yeyin N; Demir M; Abuqbeitah M; Gülsen F; Sayman H; Sönmezoglu K
    Nucl Med Commun; 2019 May; 40(5):461-468. PubMed ID: 30896544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment.
    Yamashige D; Kawamura Y; Kobayashi M; Shindoh J; Kobayashi Y; Okubo S; Muraishi N; Kajiwara A; Iritani S; Fujiyama S; Hosaka T; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Ikeda K; Arase Y; Hashimoto M; Kumada H
    Oncology; 2021; 99(3):169-176. PubMed ID: 33207358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surrogate Imaging Biomarkers of Response of Colorectal Liver Metastases After Salvage Radioembolization Using 90Y-Loaded Resin Microspheres.
    Shady W; Sotirchos VS; Do RK; Pandit-Taskar N; Carrasquillo JA; Gonen M; Sofocleous CT
    AJR Am J Roentgenol; 2016 Sep; 207(3):661-70. PubMed ID: 27384594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soft Tissue Sarcoma Response to Two Cycles of Neoadjuvant Chemotherapy: A Multireader Analysis of MRI Findings and Agreement with RECIST Criteria and Change in SUVmax.
    Favinger JL; Hippe DS; Davidson DJ; Elojeimy S; Roth ES; Lindberg AW; Ha AS
    Acad Radiol; 2018 Apr; 25(4):470-475. PubMed ID: 29273189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging for assessment of treatment response in hepatocellular carcinoma: Current update.
    Hayano K; Lee SH; Sahani DV
    Indian J Radiol Imaging; 2015; 25(2):121-8. PubMed ID: 25969635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
    Shang J; Ling X; Zhang L; Tang Y; Xiao Z; Cheng Y; Guo B; Gong J; Huang L; Xu H
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1945-53. PubMed ID: 27236466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
    Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
    Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.
    Lencioni R; Llovet JM
    Semin Liver Dis; 2010 Feb; 30(1):52-60. PubMed ID: 20175033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of lung tumor response to therapy: Current and emerging techniques.
    Coche E
    Diagn Interv Imaging; 2016 Oct; 97(10):1053-1065. PubMed ID: 27693090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer.
    Riedl CC; Pinker K; Ulaner GA; Ong LT; Baltzer P; Jochelson MS; McArthur HL; Gönen M; Dickler M; Weber WA
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1428-1437. PubMed ID: 28462446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of response after SBRT for liver tumors.
    Tétreau R; Llacer C; Riou O; Deshayes E
    Rep Pract Oncol Radiother; 2017; 22(2):170-175. PubMed ID: 28490989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response Evaluation Criteria in Solid Tumors (RECIST) and PET Response Criteria in Solid Tumors (PERCIST) for response evaluation of the neck after chemoradiotherapy in head and neck squamous cell carcinoma.
    Kishikawa T; Suzuki M; Takemoto N; Fukusumi T; Michiba T; Hanamoto A; Tanaka H; Tatsumi M; Isohashi F; Seo Y; Tamari K; Ogawa K; Inohara H
    Head Neck; 2021 Apr; 43(4):1184-1193. PubMed ID: 33368784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffusion-Weighted MRI in the Assessment of Early Treatment Response in Patients with Squamous-Cell Carcinoma of the Head and Neck: Comparison with Morphological and PET/CT Findings.
    Martins EB; Chojniak R; Kowalski LP; Nicolau UR; Lima EN; Bitencourt AG
    PLoS One; 2015; 10(11):e0140009. PubMed ID: 26562784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of fluorodeoxyglucose-positron emission tomography in the identification of new lesions in lung cancer patients for the assessment of therapy response.
    Obrzut S; Bykowski J; Badran K; Hayeri MR; Hoh CK
    Nucl Med Commun; 2010 Dec; 31(12):1008-15. PubMed ID: 20926977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.